<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72301">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02050542</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00514-41</org_study_id>
    <secondary_id>SC 3065</secondary_id>
    <nct_id>NCT02050542</nct_id>
  </id_info>
  <brief_title>Study of Current Practice Which Compare the Rate of Prostate Cancer by Using 2 Kind of Transrectal Biopsies: 3 by IRM-echography Image Fusion and 12 Systematized Guided Echographies.</brief_title>
  <acronym>MURIELLE</acronym>
  <official_title>Comparison of Prostate Cancer Detection Rates Obtained With Multiparametric MRI Targeted Transrectal Ultrasound Biopsies and Systematic Transrectal Ultrasound Biopsies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to show that 3 targeted biopsies on the suspicious image
      detected by IRM,  guided by a fusion of MRI and ultrasound- images with the Koelis ® system,
      will get no lower rate of cancer detection than those obtained by 12 systematic transrectal
      ultrasound-guided biopsies of the prostate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The act of current practice evaluated by this research is the act of prostate biopsies : the
      patient will have to undergo 12 systematized transrectal echography guided biopsies of the
      prostate and 3 additional biopsies targeted on the suspicious lesion detected with MRI,
      which are both done in current practice.

        -  A first operator is not informed of the location of the target. He will perform a
           series of 12 systematic transrectal ultrasound-guided biopsies of the prostate.

        -  Immediately after the second operator will perform 3 additional targeted biopsies on
           the suspicious image detected by IRM,  guided by a fusion of MRI and ultrasound- images
           with the Koelis ® system

      Act added by the research: Using a fusion of  MRI - ultrasound images software system
      (Koelis ®).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Carcinomatous invasion on biopsies samples</measure>
    <time_frame>Day 15</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The presence of carcinomatous invasion on biopsies samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue length of biopsy invaded by the detected cancer</measure>
    <time_frame>Day 15</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maximal tissue length  of  biopsy invaded by the detected cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy Gleason score of the detected cancer</measure>
    <time_frame>Day 15</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maximal biopsy Gleason score of the detected cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respective duration of each biopsy protocol</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Prostate Cancer Based on a Rise of the PSA &gt; 4 ng / mL.</condition>
  <arm_group>
    <arm_group_label>Targeted biopsies guided by a fusion of MRI and ultrasound</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM,  guided by a fusion of MRI and ultrasound- images with the Koelis ® system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systematic biopsies</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>systematic biopsies</intervention_name>
    <description>90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate</description>
    <arm_group_label>Targeted biopsies guided by a fusion of MRI and ultrasound</arm_group_label>
    <arm_group_label>Systematic biopsies</arm_group_label>
    <other_name>Ultrasound-guided biopsies of the prostate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted biopsies guided by a fusion of MRI and ultrasound- images</intervention_name>
    <description>Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM,  guided by a fusion of MRI and ultrasound- images with the Koelis ® system</description>
    <arm_group_label>Targeted biopsies guided by a fusion of MRI and ultrasound</arm_group_label>
    <arm_group_label>Systematic biopsies</arm_group_label>
    <other_name>Biopsies of the prostate by fusion of MRI and ultrasound- images with the Koelis ® system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient from 45 to 75 years old;

          -  Serum level  of PSA &gt; 4,0 ng / mL;

          -  Multiparametric prostate IRM, performed before inclusion and which confirm the
             diagnosis of suspected target;

          -  No opposition of the patient notified in the medical record

          -  patient member in a national insurance scheme.

        Exclusion Criteria:

          -  Previous prostate biopsy;

          -  suspicious digital rectal examination;

          -  serum PSA &gt; 20,0 ng / mL;

          -  treatment with 5 alpha reductase inhibitor during the last 3 months;

          -  untreated urinary infection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Cornud, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AP-HP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Barry Delongchamps</last_name>
    <phone>00 33 1 58 41 27 40</phone>
    <email>nicolasbdl@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Lecomte</last_name>
    <phone>00 33 1 58 41 35 45</phone>
    <email>laurence.lecomte@cch.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Luc Descotes, PhD</last_name>
      <phone>00 33 4 76 76 59 22</phone>
      <email>jldescotes@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastien Crouzet, PhD</last_name>
      <phone>00 33 14 72 11 91 91</phone>
      <email>sebastien.crouzet@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pitié salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Mozer, PhD</last_name>
      <phone>00 33 1 42 17 72 97</phone>
      <email>pierre.mozer@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Barry Delongchamps</last_name>
      <phone>00 33 1 58 41 27 40</phone>
      <email>nicolasbdl@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Laurence Lecomte, PhD</last_name>
      <phone>00 33 1 58 41 35 45</phone>
      <email>laurence.lecomte@cch.aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Michel Casanova, PhD</last_name>
      <phone>00 33 1 60 61 11 00</phone>
      <email>consultation@clinique-stjeandedieu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erci Bruguiere, PhD</last_name>
      <phone>00 33 5 62 21 16 16</phone>
      <email>bruguiere.eric@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Malavaud, PhD</last_name>
      <phone>00 33 5 61 32 32 29</phone>
      <email>malavaud.b@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>prostate</keyword>
  <keyword>PSA</keyword>
  <keyword>biopsies</keyword>
  <keyword>ultrasound</keyword>
  <keyword>MRI</keyword>
  <keyword>fusion of images</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
